Please provide your email address to receive an email when new articles are posted on . Etelcalcetide use decreased 58% after the transitional drug add-on payment adjustment ended. Mean parathyroid ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on drug for type 1 diabetes and chronic kidney disease, the company ...

Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...